Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 4/20 | 0.31 |
| ▸ | CES1 | P23141 | 4/20 | 0.31 |
| ▸ | CES2 | O00748 | 3/20 | 0.31 |
| ▸ | PLA2G6 | O60733 | 1/20 | 0.31 |
| ▸ | GMNN | O75496 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 2/20 | 0.30 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.30 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2593550 | 1.00 | FAAH (0.31) | FAAHCES1CES2PLA2G6GMNN | |
| SCHEMBL2232709 | 0.93 | NOS3 (0.35) | — | |
| SCHEMBL3344976 | 0.85 | TDP1 (0.31) | — | |
| SCHEMBL18338077 | 0.85 | NAAA (0.31) | — | |
| SCHEMBL15669243 | 0.85 | EPHX1 (0.34) | FAAHCES1CES2PLA2G6GMNN | |
| SCHEMBL28066542 | 0.84 | — | — | |
| SCHEMBL20317588 | 0.84 | — | — | |
| SCHEMBL20097741 | 0.82 | HDAC3 (0.36) | FAAHCES1CES2PLA2G6GMNN | |
| SCHEMBL23398347 | 0.81 | LMNA (0.36) | HSD17B10 | |
| SCHEMBL17556641 | 0.81 | LMNA (0.36) | HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220387369-A1 | Prooxidative chain-transfer agents for use in the treatment of malignant tumour or infectious diseases | UNIVERSITÄTSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITÄT MAINZ (DE) | 2022-12-08 | — | — | US | claimed |
| EP-4065095-A1 | PROOXIDATIVE CHAIN-TRANSFER AGENTS FOR USE IN THE TREATMENT OF MALIGNANT TUMOUR OR INFECTIOUS DISEASES | Universitätsmedizin der Johannes Gutenberg-Universität Mainz (DE) | 2022-10-05 | — | — | EP | claimed |
| WO-2021105435-A1 | PROOXIDATIVE CHAIN-TRANSFER AGENTS FOR USE IN THE TREATMENT OF MALIGNANT TUMOUR OR INFECTIOUS DISEASES | UNIVERSITÄTSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITÄT MAINZ (DE) | 2021-06-03 | — | — | WO | claimed |
| EP-3827816-A1 | PROOXIDATIVE CHAIN-TRANSFER AGENTS FOR USE IN THE TREATMENT OF MALIGNANT TUMOUR OR INFECTIOUS DISEASES | Universitätsmedizin der Johannes Gutenberg-Universität Mainz (DE) | 2021-06-02 | — | — | EP | claimed |
| US-20220387369-A1 | Prooxidative chain-transfer agents for use in the treatment of malignant tumour or infectious diseases | UNIVERSITÄTSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITÄT MAINZ (DE) | 2022-12-08 | — | — | US | disclosed |
| EP-4065095-A1 | PROOXIDATIVE CHAIN-TRANSFER AGENTS FOR USE IN THE TREATMENT OF MALIGNANT TUMOUR OR INFECTIOUS DISEASES | Universitätsmedizin der Johannes Gutenberg-Universität Mainz (DE) | 2022-10-05 | — | — | EP | disclosed |
| WO-2021105435-A1 | PROOXIDATIVE CHAIN-TRANSFER AGENTS FOR USE IN THE TREATMENT OF MALIGNANT TUMOUR OR INFECTIOUS DISEASES | UNIVERSITÄTSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITÄT MAINZ (DE) | 2021-06-03 | — | — | WO | disclosed |
| EP-3827816-A1 | PROOXIDATIVE CHAIN-TRANSFER AGENTS FOR USE IN THE TREATMENT OF MALIGNANT TUMOUR OR INFECTIOUS DISEASES | Universitätsmedizin der Johannes Gutenberg-Universität Mainz (DE) | 2021-06-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220387369-A1 | Prooxidative chain-transfer agents for use in the treatment of malignant tumour or infectious diseases | SLC25A1, SLC19A2, SLC25A21 | FAAH 3083/4885CES1 1227/4885CES2 1206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.